Natalia Martin Orozco
Chief Scientific Officer Providence Therapeutics
Dr. Natalia Martin Orozco is the Chief Science Officer of Providence Therapeutics. Currently she leads a team of scientists and engineers to develop vaccines, and cancer therapeutics. Natalia has more than 17 years’ experience in drug development in both industry and academia. Prior positions include leading target discovery and drug development teams taking assets through regulatory approvals for clinical trials including personalized cell therapies and biologics both for cancer and autoimmunity.
Natalia served as Principal Scientist at Bellicum Pharmaceuticals, LION Biotechnology (now IOVANCE) and EMD Serono, before joining Providence Therapeutics as VP of Drug Development in 2018. In the last 8 years, Natalia led the effort to establish an mRNA platform at Providence, from antigen design to final lipid formulation product. She has been developing cancer assets as well as infectious disease vaccines.
Seminars
- Introducing the Brain tumor antigen landscape and opportunities for personalized mRNA Therapeutics
- Presenting the PAEDNEOVAX trial phase I/II clinical trial evaluating a personalised mRNA vaccine in children and adolescents with relapsed/refractory brain tumours (including medulloblastoma, ependymoma and high grade glioma) and newly diagnosed Diffuse Midline Glioma (DMG)
- Unveiling the strategy to provide the mRNA therapeutic on time for treatment and preliminary results
